156 related articles for article (PubMed ID: 34459025)
1. Omecamtiv mecarbil attenuates length-tension relationship in healthy rat myocardium and preserves it in monocrotaline-induced pulmonary heart failure.
Lookin O; Kuznetsov D; Protsenko Y
Clin Exp Pharmacol Physiol; 2022 Jan; 49(1):84-93. PubMed ID: 34459025
[TBL] [Abstract][Full Text] [Related]
2. The lack of slow force response in failing rat myocardium: role of stretch-induced modulation of Ca-TnC kinetics.
Lookin O; Protsenko Y
J Physiol Sci; 2019 Mar; 69(2):345-357. PubMed ID: 30560346
[TBL] [Abstract][Full Text] [Related]
3. Dose-Dependent Effects of the Myosin Activator Omecamtiv Mecarbil on Cross-Bridge Behavior and Force Generation in Failing Human Myocardium.
Mamidi R; Li J; Gresham KS; Verma S; Doh CY; Li A; Lal S; Dos Remedios CG; Stelzer JE
Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29030372
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analyses of the inotropic compound omecamtiv mecarbil in rat and human cardiac preparations.
Rhoden A; Schulze T; Pietsch N; Christ T; Hansen A; Eschenhagen T
Am J Physiol Heart Circ Physiol; 2022 Mar; 322(3):H373-H385. PubMed ID: 35030072
[TBL] [Abstract][Full Text] [Related]
5. Omecamtiv mecarbil evokes diastolic dysfunction and leads to periodic electromechanical alternans.
Fülöp GÁ; Oláh A; Csipo T; Kovács Á; Pórszász R; Veress R; Horváth B; Nagy L; Bódi B; Fagyas M; Helgadottir SL; Bánhegyi V; Juhász B; Bombicz M; Priksz D; Nanasi P; Merkely B; Édes I; Csanádi Z; Papp Z; Radovits T; Tóth A
Basic Res Cardiol; 2021 Apr; 116(1):24. PubMed ID: 33844095
[TBL] [Abstract][Full Text] [Related]
6. Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity.
Bakkehaug JP; Kildal AB; Engstad ET; Boardman N; Næsheim T; Rønning L; Aasum E; Larsen TS; Myrmel T; How OJ
Circ Heart Fail; 2015 Jul; 8(4):766-75. PubMed ID: 26025342
[TBL] [Abstract][Full Text] [Related]
7. Omecamtiv Mecarbil: A Myosin Motor Activator Agent with Promising Clinical Performance and New in vitro Results.
Nanasi P; Komaromi I; Gaburjakova M; Almassy J
Curr Med Chem; 2018; 25(15):1720-1728. PubMed ID: 29278207
[TBL] [Abstract][Full Text] [Related]
8. The energy-saving effect of a new myosin activator, omecamtiv mecarbil, on LV mechanoenergetics in rat hearts with blood-perfused isovolumic contraction model.
Obata K; Morita H; Takaki M
Naunyn Schmiedebergs Arch Pharmacol; 2019 Sep; 392(9):1065-1070. PubMed ID: 31267148
[TBL] [Abstract][Full Text] [Related]
9. Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (-)-noradrenaline.
Dashwood A; Cheesman E; Wong YW; Haqqani H; Beard N; Hay K; Spratt M; Chan W; Molenaar P
Pharmacol Res Perspect; 2021 May; 9(3):e00760. PubMed ID: 33929079
[TBL] [Abstract][Full Text] [Related]
10. Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.
Liu LC; Dorhout B; van der Meer P; Teerlink JR; Voors AA
Expert Opin Investig Drugs; 2016; 25(1):117-27. PubMed ID: 26587768
[TBL] [Abstract][Full Text] [Related]
11. The use of Ca-transient to evaluate Ca
Lookin O
Clin Exp Pharmacol Physiol; 2020 Nov; 47(11):1824-1833. PubMed ID: 32654202
[TBL] [Abstract][Full Text] [Related]
12. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.
Teerlink JR; Felker GM; McMurray JJV; Ponikowski P; Metra M; Filippatos GS; Ezekowitz JA; Dickstein K; Cleland JGF; Kim JB; Lei L; Knusel B; Wolff AA; Malik FI; Wasserman SM;
J Am Coll Cardiol; 2016 Mar; 67(12):1444-1455. PubMed ID: 27012405
[TBL] [Abstract][Full Text] [Related]
13. Contractile Behavior of Right Atrial Myocardium of Healthy Rats and Rats with the Experimental Model of Pulmonary Hypertension.
Lookin O; Mukhlynina E; Protsenko Y
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457003
[TBL] [Abstract][Full Text] [Related]
14. Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction.
Psotka MA; Teerlink JR
Handb Exp Pharmacol; 2017; 243():465-490. PubMed ID: 28315072
[TBL] [Abstract][Full Text] [Related]
15. Omecamtiv mecarbil augments cardiomyocyte contractile activity both at resting and systolic Ca
Ráduly AP; Tóth A; Sárkány F; Horváth B; Szentandrássy N; Nánási PP; Csanádi Z; Édes I; Papp Z; Borbély A
ESC Heart Fail; 2023 Apr; 10(2):1326-1335. PubMed ID: 36722665
[TBL] [Abstract][Full Text] [Related]
16. The length-dependent activation of contraction is equally impaired in impuberal male and female rats in monocrotaline-induced right ventricular failure.
Lookin O; Balakin A; Kuznetsov D; Protsenko Y
Clin Exp Pharmacol Physiol; 2015 Nov; 42(11):1198-206. PubMed ID: 26234534
[TBL] [Abstract][Full Text] [Related]
17. Frequency-dependent effects of omecamtiv mecarbil on cell shortening of isolated canine ventricular cardiomyocytes.
Horváth B; Szentandrássy N; Veress R; Almássy J; Magyar J; Bányász T; Tóth A; Papp Z; Nánási PP
Naunyn Schmiedebergs Arch Pharmacol; 2017 Dec; 390(12):1239-1246. PubMed ID: 28940010
[TBL] [Abstract][Full Text] [Related]
18. Calcium mishandling impairs contraction in right ventricular hypertrophy prior to overt heart failure.
Power AS; Hickey AJ; Crossman DJ; Loiselle DS; Ward ML
Pflugers Arch; 2018 Jul; 470(7):1115-1126. PubMed ID: 29525825
[TBL] [Abstract][Full Text] [Related]
19. The myosin activator omecamtiv mecarbil improves wall stress in a rat model of chronic aortic regurgitation.
El Oumeiri B; van de Borne P; Hubesch G; Herpain A; Annoni F; Jespers P; Stefanidis C; Mc Entee K; Vanden Eynden F
Physiol Rep; 2021 Aug; 9(16):e14988. PubMed ID: 34405966
[TBL] [Abstract][Full Text] [Related]
20. Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C.
Mamidi R; Gresham KS; Li A; dos Remedios CG; Stelzer JE
J Mol Cell Cardiol; 2015 Aug; 85():262-72. PubMed ID: 26100051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
